Target Name: MIR5787
NCBI ID: G102464817
Review Report on MIR5787 Target / Biomarker Content of Review Report on MIR5787 Target / Biomarker
MIR5787
Other Name(s): MicroRNA 5787 | hsa-miR-5787 | hsa-mir-5787 | microRNA 5787

miRNA-5787: A Potential Drug Target and Biomarker

MicroRNA 5787 (miRNA-5787) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have shed light on its role in various biological processes.

The miRNA-5787 molecule has a length of approximately 200 nucleotides and consists of 19 coding and non-coding regions. It is expressed in various tissues and cells of the body and has been shown to play a role in various biological processes, including cell growth, differentiation, and apoptosis.

One of the most significant functions of miRNA-5787 is its role in cell apoptosis. Apoptosis is a natural process that is essential for the development and maintenance of tissues and organs, and it is regulated by various factors, including miRNA-5787. studies have shown that miRNA-5787 can induce apoptosis in various cell types and that its levels are often decreased in diseases, such as cancer.

Another function of miRNA-5787 is its role in cell proliferation. miRNA-5787 has been shown to inhibit the growth of various cell types, including cancer cells, and it has been proposed as a potential therapeutic target for cancer treatment.

In addition to its role in cell biology, miRNA-5787 has also been shown to have potential as a drug target. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have shown that miRNA-5787 can be blocked by small interfering RNA (siRNA), a technique that can be used to reduce the levels of miRNA-5787 in cells.

One of the most promising strategies for targeting miRNA-5787 is the use of small interfering RNA (siRNA). SiRNA is a natural molecule that can interact with miRNA-5787 and can be used to reduce its levels in cells. Studies have shown that siRNA can effectively inhibit the levels of miRNA-5787 in various cell types, including cancer cells.

In addition to its potential as a drug target, miRNA-5787 has also been shown to have potential as a biomarker for various diseases, including cancer. Its levels can be affected by various factors, including age, diet, and environmental conditions, which can affect its levels in the body.Studies have shown that miRNA-5787 levels can be used as a biomarker for various diseases, including cancer, and that its levels can be affected by various factors, including age, diet, and environmental conditions.

In conclusion, miRNA-5787 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have shed light on its role in various biological processes. The use of small interfering RNA (siRNA) is a promising strategy for targeting miRNA-5787 and its levels can be used as a biomarker for various diseases. Further research is needed to fully understand the role of miRNA-5787 in various biological processes and its potential as a drug target and biomarker.

Protein Name: MicroRNA 5787

The "MIR5787 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5787 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR579 | MIR580 | MIR581 | MIR582 | MIR583 | MIR584 | MIR585 | MIR586 | MIR587 | MIR588 | MIR589 | MIR590 | MIR591 | MIR592 | MIR593 | MIR595 | MIR596 | MIR597 | MIR598 | MIR599 | MIR600 | MIR600HG | MIR601 | MIR602 | MIR603 | MIR604 | MIR605 | MIR606 | MIR6068 | MIR6069 | MIR607 | MIR6070 | MIR6071 | MIR6072 | MIR6073 | MIR6074 | MIR6075 | MIR6076 | MIR6077 | MIR6078 | MIR608 | MIR6080 | MIR6081 | MIR6082 | MIR6083 | MIR6084 | MIR6085 | MIR6086 | MIR6088 | MIR6089 | MIR609 | MIR6090 | MIR610 | MIR611 | MIR612 | MIR6124 | MIR6125 | MIR6126 | MIR6127 | MIR6128 | MIR6129 | MIR613 | MIR6130 | MIR6131 | MIR6132 | MIR6133 | MIR6134 | MIR614 | MIR615 | MIR616 | MIR6165 | MIR617 | MIR618 | MIR619 | MIR620 | MIR621 | MIR622 | MIR623 | MIR624 | MIR625 | MIR626 | MIR627 | MIR628 | MIR629 | MIR630 | MIR631 | MIR632 | MIR633 | MIR634 | MIR635 | MIR636 | MIR637 | MIR638 | MIR639 | MIR640 | MIR641 | MIR642A | MIR642B | MIR643 | MIR644A